Project Grant R01AI186812
Award Date
8/1/24
Completion Date
6/30/29
Dollars Obligated
$1.5M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30303, USA
Similar Awards
This Project Grant award, totaling $859,597, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award aims to develop a vaccine that can elicit broadly neutralizing antibodies (bNAbs) against the HIV-1 fusion peptide epitope, a major vulnerable site on the viral envelope protein. The key product being developed is a recombinant fusion immunogen combining the HIV-1 fusion peptide with...
This $760,038 federal Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The grant supports research by George Mason University to study the anti-HIV properties of the PSGL-1 protein, a newly identified HIV restriction factor. The research aims to determine the structure-function relationship of the PSGL-1 DR domain and its impact on anti-HIV activity through a combination of...
This Project Grant award of $910,905 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research by the Scripps Research Institute to develop an HIV vaccine using a lipid nanodisc platform. The key objectives are to: Solve the structures of engineered transmembrane HIV envelope (Env) proteins incorporated into lipid nanodiscs in complex with broadly neutralizing antibodies targeting the...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Colorado State University a $340,408 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate an assay for precision antiretroviral therapy to combat drug resistance in HIV patients. The key products and services to be delivered under this award include: Improving the throughput and capacity of an existing infectivity assay using proviral constructs with an H2B-mRFP...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $242,310.00 to Emory University to study the role of immunoglobulin genetic diversity in the development of neutralizing antibodies against the HIV envelope protein. The project aims to identify genetic polymorphisms and alleles in rhesus macaques associated with differential development of neutralizing...
The federal Project Grant award R01AI187016 for $737,761.00, awarded on August 1, 2024 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to enhance HIV prevention through a vaccine approach that promotes durable immunity. The key objectives are to induce robust CD4 T follicular helper (TFH) cells, which are essential for vigorous B cell activity within germinal centers, to facilitate the...
This Project Grant award of $223,300.00, awarded on January 17, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop novel antiviral compounds targeting the HIV capsid protein. The goal is to generate compounds that can effectively inhibit HIV strains resistant to the recently approved capsid-targeting drug lenacapavir. Key aims include synthesis of analogs designed to...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,547,482.00 to Trustees of Dartmouth College to conduct research aimed at improving the antiviral activity of broadly neutralizing antibodies (BNAbs) against HIV. The project will investigate two strategies to enhance BNAb effectiveness: 1) engineering the Fc region to improve BNAb effector function, and 2)...
This Project Grant award for $1,314,572.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research aimed at developing a cure strategy for HIV-1 using CD4-mimetic compounds (CD4MCs) and CD4-induced antibodies (CD4I Abs). The research, conducted by Yale University, leverages the recent discovery of a new class of indoline CD4MCs that display improved antiviral potency and breadth...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $194,616.00 to Emory University to develop virus-like particles (VLPs) for an HIV-1 cure strategy. The key objectives are to: Use VLPs to deliver the HIV-1 Tat protein as a latency reversing agent, paired with AAV vectors expressing broadly neutralizing antibodies to eliminate reactivated HIV-infected cells (the...